王子製藥 6935.TW Overview
6935
王子製藥
-3.24%
(-0.03)
6935 AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
6935 Current Performance
-3.14%
王子製藥
-0.22%
Avg of Sector
1.17%
TAIEX
6935 Key Information
6935 Revenue by Segments
Browsing restrictions can be lifted for a fee.
6935 Net Income
Browsing restrictions can be lifted for a fee.
6935 Cash Flow
Browsing restrictions can be lifted for a fee.
6935 Profit Margin
Browsing restrictions can be lifted for a fee.
6935 PE Ratio River
Browsing restrictions can be lifted for a fee.
6935 Profile
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin c tablets, vitamin b complex tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potassium cresolsulfonate, fusultiamine hydrochloride, and fursultiamine. It supplies its products to Spain and Europe. Prince Pharmaceutical Co., Ltd. was founded in 1962 and is headquartered in Yunlin County, Taiwan.
6935 FAQ
When is 6935's latest earnings report released?
The most recent financial report for 王子製藥 (6935) covers the period of 2024Q4 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6935's short-term business performance and financial health. For the latest updates on 6935's earnings releases, visit this page regularly.
What is the operating profit of 6935?
According to the latest financial report, 王子製藥 (6935) reported an Operating Profit of -24.08M with an Operating Margin of -6.88% this period, representing a decline of 256.77% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is 6935's revenue growth?
In the latest financial report, 王子製藥 (6935) announced revenue of 350.21M, with a Year-Over-Year growth rate of -11.86%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does 6935 have?
At the end of the period, 王子製藥 (6935) held Total Cash and Cash Equivalents of 102.8M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does 6935 go with three margins increasing?
In the latest report, 王子製藥 (6935) did not achieve the “three margins increasing” benchmark, with a gross margin of 10.42%%, operating margin of -6.88%%, and net margin of -8.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6935's profit trajectory and future growth potential.
Is 6935's EPS continuing to grow?
According to the past four quarterly reports, 王子製藥 (6935)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.78. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.